Launch of Subcutaneous Injection Formulation, Actemra®, for a Treatment of Rheumatoid Arthritis The First Anti-IL-6 Receptor Antibody in Subcutaneous Market
May 24, 2013
Launch of Subcutaneous Injection Formulation, Actemra®, for a Treatment of Rheumatoid Arthritis The First Anti-IL-6 Receptor Antibody in Subcutaneous Market
Launch of Subcutaneous Injection Formulation, Actemra®, for a Treatment of Rheumatoid Arthritis The First Anti-IL-6 Receptor Antibody in Subcutaneous Market
